Viatris Inc
NASDAQ:VTRS
Viatris Inc
Revenue
Viatris Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Viatris Inc
NASDAQ:VTRS
|
Revenue
$15.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45B
|
CAGR 3-Years
2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$60.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Viatris Inc
Revenue Breakdown
Breakdown by Geography
Viatris Inc
Breakdown by Segments
Viatris Inc
Total Revenue:
15.4B
USD
|
Net Sales:
15.4B
USD
|
Brands:
9.8B
USD
|
Generics:
5.6B
USD
|
Lipitor ®:
1.6B
USD
|
Norvasc ®:
732.4m
USD
|
Lyrica ®:
556.5m
USD
|
Epipen® Auto-Injectors:
442.2m
USD
|
Viagra ®:
428.8m
USD
|
Celebrex ®:
330.6m
USD
|
Creon ®:
304.9m
USD
|
Effexor ®:
262.9m
USD
|
Zoloft ®:
235.7m
USD
|
Yupelri ®:
220.8m
USD
|
Dymista ®:
200m
USD
|
Xalabrands:
193.2m
USD
|
Influvac ®:
192.4m
USD
|
Amitiza ®:
157m
USD
|
Xanax ®:
154.8m
USD
|
See Also
What is Viatris Inc's Revenue?
Revenue
15.4B
USD
Based on the financial report for Dec 31, 2023, Viatris Inc's Revenue amounts to 15.4B USD.
What is Viatris Inc's Revenue growth rate?
Revenue CAGR 10Y
8%
Over the last year, the Revenue growth was -5%. The average annual Revenue growth rates for Viatris Inc have been 9% over the past three years , 6% over the past five years , and 8% over the past ten years .